PeptidePedia The community reference

Injection site rotation: difference between revisions

Diff·revision 1 → 2·06:20, 12 Sep 2024

Difference between revision 1 and revision 2 of Injection site rotation. 5 lines changed; the page grew by 574 bytes.

Revision 1 — 19:51, 10 Sep 2024
FlowTrialFraser (talk)
new article: dosing and handling, expansion welcome
1,581 bytes +1,581
Revision 2 — 06:20, 12 Sep 2024
INN_Ingrid (talk)
expand §Rotation schemes
2,155 bytes +574
10The evidence base is largely from insulin therapy, where lipohypertrophy is common, is associated with unpredictable glycaemic control, and resolves slowly when the affected area is rested. Its relevance to weekly peptide administration is less well characterised, since injection frequency is roughly one seventh of that in basal-bolus insulin therapy.{{r|gentile2016}}10The evidence base is largely from insulin therapy, where lipohypertrophy is common, is associated with unpredictable glycaemic control, and resolves slowly when the affected area is rested. Its relevance to weekly peptide administration is less well characterised, since injection frequency is roughly one seventh of that in basal-bolus insulin therapy.{{r|gentile2016}}
1111
+12== Lipohypertrophy ==
+13Lipohypertrophy is a local proliferation of subcutaneous adipose tissue at sites of repeated injection. It presents as a soft or rubbery thickening, often more readily felt than seen, and is frequently painless — which is part of why it is under-recognised.{{r|gentile2016}}
+14
+15Absorption from affected tissue is reduced and more variable. In insulin therapy this produces unexplained variability that persists until the affected area is rested, and continued injection into it is self-reinforcing because reduced sensation makes the site attractive.
+16
12== References ==17== References ==
13{{reflist}}18{{reflist}}